Holowesko Partners Ltd. Purchases New Holdings in Kenvue Inc. $KVUE

Holowesko Partners Ltd. purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 358,000 shares of the company’s stock, valued at approximately $6,176,000. Kenvue accounts for approximately 2.1% of Holowesko Partners Ltd.’s portfolio, making the stock its 15th largest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. increased its stake in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after acquiring an additional 618 shares during the period. Elyxium Wealth LLC bought a new position in Kenvue during the fourth quarter valued at about $26,000. SBI Securities Co. Ltd. increased its stake in Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after acquiring an additional 1,027 shares during the period. Atlantic Union Bankshares Corp increased its stake in Kenvue by 184.1% during the third quarter. Atlantic Union Bankshares Corp now owns 2,619 shares of the company’s stock valued at $43,000 after acquiring an additional 1,697 shares during the period. Finally, Leonteq Securities AG bought a new position in Kenvue during the fourth quarter valued at about $45,000. 97.64% of the stock is currently owned by institutional investors.

Insider Transactions at Kenvue

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.59% of the company’s stock.

Kenvue Stock Up 0.0%

Shares of KVUE opened at $17.72 on Monday. The company has a market capitalization of $34.01 billion, a P/E ratio of 20.84, a PEG ratio of 1.34 and a beta of 0.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87. The business’s 50 day simple moving average is $17.37 and its 200-day simple moving average is $17.48.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same period in the previous year, the business earned $0.24 EPS. Kenvue’s revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts predict that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue’s dividend payout ratio is currently 97.65%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KVUE. Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Weiss Ratings lowered Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. Canaccord Genuity Group boosted their price target on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Barclays lowered their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Finally, Citigroup lowered their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.